Evidence map›Paper›PMID 39041261›Full record

ArticleEndocrine, metabolic & immune disorders drug targets2025

TNF-alpha Inhibitors Induced Eosinophilia: A Case Report of an Undervalued Side Effect of Such Biologicals.

Federico Diomeda, Gianfranco Calogiuri, Maurizio Congedo, Angela Filoni, Emiliano Sordi, Massimo Fiore, Lucia Pietroleonardo, Prisco Piscitelli, Adele Civino

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Endocrine, metabolic & immune disorders drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Federico DiomedaDepartment of Pediatric Immunology and Rheumatology, Vito Fazzi Hospital, Lecce, Italy.
Gianfranco CalogiuriUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Maurizio CongedoUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Angela FiloniUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Emiliano SordiUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Massimo FioreUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Lucia PietroleonardoUnit of Dermatology and Allergy, Vito Fazzi Hospital, Lecce, Italy.
Prisco PiscitelliDepartment of Experimental Medicine, University of Salento, Lecce, Italy.
Adele CivinoDepartment of Pediatric Immunology and Rheumatology, Vito Fazzi Hospital, Lecce, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe present an unusual case of a 28-year-old rheumatologic male patient who developed eosinophilia while he was on etanercept therapy previously and then on golimumab. CASE REPRESENTATION: Although eosinophilia is rarely reported in the literature as a side-effect of various Tumor Necrosis Factor-alpha (TNF-alpha) antagonists, it represents a riddle about the future treatments of these patients since the persistence of therapy might lead to the onset of dermatologic or visceral eosinophilic complications in such patients.

conclusionFurthermore, the pathogenesis of eosinophilia is still unknown, and all the proposed hypotheses do not explain the eosinophilic proliferation in certain subjects.

Indexed as

Antibodies, MonoclonalAntirheumatic AgentsBiological ProductsEosinophiliaTumor Necrosis Factor-alphaAdultEtanerceptHumansMaleAntibodies, MonoclonalAntirheumatic AgentsBiological ProductsEtanerceptgolimumabTumor Necrosis Factor-alphaEosinophiliaetanerceptgolimumabhematologic side effectstherapy.tumor necrosis factor-alpha inhibitors

Identifiers

PMID39041261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.